

## Contents

*List of contributors*

*page viii*

### **Part I Introduction**

- 1 Genes and psychopharmacology: exploring the interface 3  
Bernard Lerer

### **Part II Clinical background and research design**

- 2 From pharmacogenetics to pharmacogenomics of psychotropic drug response 21  
Anil K. Malhotra
- 3 Neuropsychopharmacology: the interface between genes and psychiatric nosology 36  
Thomas A. Ban
- 4 Methodological issues in psychopharmacogenetics 57  
Sheldon H. Preskorn
- 5 Statistical approaches in psychopharmacogenetics 72  
Fabio Macciardi

### **Part III Molecular background**

- 6 The psychopharmacogenetic–neurodevelopmental interface in serotonergic gene pathways 95  
K. Peter Lesch, Jens Benninghoff, and Angelika Schmitt

---

**vi**      **Contents**

- 7      RNA processing regulation and interindividual variation      127  
Colleen M. Niswender and Linda K. Hutchinson

---

**Part IV    Pharmacokinetics**

- 8      Pharmacogenetics of psychotropic drug metabolism      157  
Vural Ozdemir, Angela D.M. Kashuba, Vincenzo S. Basile, and James L. Kennedy
- 9      Pharmacogenetics of chiral psychotropic drugs      181  
Pierre Baumann and Chin B. Eap

---

**Part V    Specific psychotropic drugs and disorders**

- 10     Clozapine response and genetic variation in neurotransmitter receptor targets      217  
David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama, and Robert W. Kerwin
- 11     Genetic factors underlying drug-induced tardive dyskinesia      245  
Ronnen H. Segman and Bernard Lerer
- 12     Functional gene-linked polymorphic regions in pharmacogenetics      267  
Marco Catalano
- 13     Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders      283  
Emanuela Mundo and James L. Kennedy
- 14     Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex      300  
Smita A. Pandit, Spiliios V. Argyropoulos, Patrick G. Kehoe, and David J. Nutt
- 15     Genetic factors and long-term prophylaxis in bipolar disorder      320  
Martin Alda
- 16     Genetic influences on responsiveness to anticonvulsant drugs      333  
Thomas N. Ferraro
- 17     Apolipoprotein E as a marker in the treatment of Alzheimer's disease      360  
Keith Schappert, Pierre Sevigny, and Judes Poirier

**vii**      **Contents**

---

- 18      Genetic variation and drug dependence risk factors      372  
Joel Gelernter and Henry Kranzler

**Part VI**    **Pharmacogenetics and brain imaging**

---

- 19      Brain imaging and pharmacogenetics in Alzheimer's disease and  
schizophrenia      391  
Steven G. Potkin, James L. Kennedy, and Vincenzo S. Basile

**Part VII**   **Industry perspectives**

---

- 20      Pharmacogenetics in psychotropic drug discovery and development      401  
William Z. Potter, AnnCatherine Van Lone, and Larry Altstiel
- 21      High-throughput single nucleotide polymorphism genotyping      420  
Anne Shalom and Ariel Darvasi
- Index*      439